A phase i study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors Journal Article


Authors: Wang-Gillam, A.; Tew, W. P.; Rothenberg, M. L.; Dupont, J.; Cooper, W.; Sternas, L.; Buzenet, G.; Sosman, J. A.; Spriggs, D. R.; Lockhart, A. C.
Article Title: A phase i study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors
Abstract: Summary: Targeting angiogenesis is a valid anti-cancer strategy. Aflibercept is designed to sequester circulating vascular endothelial growth factor (VEGF) by preventing VEGF from binding to its receptors. This phase I study was to evaluate a new formulation of subcutaneously administered aflibercept in patients with advanced solid tumors. Here we report our experience with the toxicity, pharmacokinetic profile and efficacy of the new 100 mg/mL subcutaneous (SC) formulation of aflibercept administered at a dose of at 4 mg/kg every 2 weeks. © 2011 The Author(s).
Keywords: adult; clinical article; aged; constipation; fatigue; angiogenesis inhibitor; advanced cancer; diarrhea; drug dose reduction; drug efficacy; drug withdrawal; hypertension; side effect; solid tumor; cancer patient; anorexia; nausea; myalgia; drug dosage form comparison; cohort analysis; abdominal pain; arthralgia; backache; coughing; dyspnea; nail disease; drug induced headache; aflibercept; muscle weakness; peripheral edema; erythema; limb pain; maximum plasma concentration; drug absorption; drug blood level; phase 1 clinical trial; drug half life; connective tissue disease; glossodynia; dry skin; proteinuria; musculoskeletal disease; satiety; drug formulation; mouth pain; nose obstruction; sore throat; joint stiffness; dysphonia; musculoskeletal pain; phase i study; subcutaneously administration; dry nose; spasticity
Journal Title: Investigational New Drugs
Volume: 30
Issue: 5
ISSN: 0167-6997
Publisher: Springer  
Date Published: 2012-10-01
Start Page: 1958
End Page: 1961
Language: English
DOI: 10.1007/s10637-011-9753-y
PROVIDER: scopus
PMCID: PMC3432791
PUBMED: 22002018
DOI/URL:
Notes: --- - "Export Date: 3 December 2012" - "CODEN: INNDD" - "Source: Scopus"
Altmetric
Citation Impact
MSK Authors
  1. Jakob Dupont
    65 Dupont
  2. William P Tew
    207 Tew
  3. David R Spriggs
    325 Spriggs